GlassScriptPhysician profile
Mark H Henigan
NPI 1689897365
$8,435.75
in general payments reported to CMS, 2019-2025
19 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $661 · 2020: $1,335 · 2021: $1,798 · 2022: $1,289 · 2023: $777 · 2024: $1,211 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,352 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,351.53 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,474.65 | 2020-2025 | Caplyta |
| Abbvie INC. | $1,139.08 | 2021-2025 | |
| Lundbeck LLC | $1,070.55 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $861.74 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $794.82 | 2019-2025 | Rexulti, Abilify Maintena |
| Allergan, INC. | $772.15 | 2019-2020 | |
| Neuronetics, INC. | $418.08 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $391.62 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $309.74 | 2023-2025 | Auvelity |
| Sunovion Pharmaceuticals INC. | $214.88 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $196.66 | 2021-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $178.81 | 2019-2024 | Spravato |
| Eisai INC. | $174.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $157.60 | 2019-2023 | Belsomra |
| Ironshore Pharmaceuticals INC. | $79.81 | 2019-2023 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $69.50 | 2024-2025 | Aplenzin |
| Jazz Pharmaceuticals INC. | $68.38 | 2021 | |
| Alkermes, INC. | $43.36 | 2023-2024 | Aristada, Lybalvi |
| Shire North American Group INC | $19.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Henigan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.